Information Provided By:
Fly News Breaks for December 18, 2019
ADMS
Dec 18, 2019 | 07:15 EDT
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Adamas Pharmaceuticals to $10 from $30 after ADS-5102 did not significantly impact secondary walking measures at either dose in the INROADS study. The analyst removed all contribution from ADS-5102 in the multiple sclerosis indication from his model. However, he believes Adamas is undervalued at the current share price and thus reiterates a Buy rating.
News For ADMS From the Last 2 Days
There are no results for your query ADMS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.